---
title: "Vertex Pharmaceuticals: Business Model"
description: "Vertex Pharmaceuticals revenue by product line and geography from its fiscal 2025 Form 10-K, with each part's share, growth and profitability explained."
canonical: https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/business-model/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Vertex Pharmaceuticals: Business Model & Revenue Engine

## Direct Answer

Vertex Pharmaceuticals reports revenue across 6 product and service lines in its fiscal 2025 Form 10-K. TRIKAFTAKAFTRIO is the largest, with $10.3 billion of revenue (86% of the total), followed by ALYFTREK at $838 million (7%). 63% of revenue came from the United States.

## How Does Vertex Pharmaceuticals Make Money?

TRIKAFTAKAFTRIO supplies 86% of revenue, so Vertex Pharmaceuticals's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, CASGEVY grew fastest (+1058.0%) and TRIKAFTAKAFTRIO slowest (+0.7%), so the revenue mix tilts toward CASGEVY while that gap lasts.

| Product or service | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| TRIKAFTAKAFTRIO | $10.3 billion | $10.2 billion | 85.9% | 0.7% |
| ALYFTREK | $838 million | $0 | 7.0% | n/a |
| Manufactured Product Other | $820 million | $782 million | 6.8% | 4.9% |
| CASGEVY | $116 million | $10 million | 1.0% | 1058.0% |
| JOURNAVX | $60 million | $0 | 0.5% | n/a |
| Collaborative and Royalty | $31 million | $0 | 0.3% | n/a |

![Bar chart of Vertex Pharmaceuticals revenue by product line for fiscal 2025: TRIKAFTAKAFTRIO 85.9%, ALYFTREK 7.0%, Manufactured Product Other 6.8%, CASGEVY 1.0%, JOURNAVX 0.5%, Collaborative and Royalty 0.3%.](https://www.getswoopr.com/images/charts/vertex-pharmaceuticals-business-model-segment-mix.webp)
*Vertex Pharmaceuticals revenue by product line as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.*

## Where Does Vertex Pharmaceuticals's Revenue Come From?

Regions follow the definitions in the filing; most companies assign revenue by customer location.

| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| United States | $7.5 billion | $6.7 billion | 62.9% | 12.9% |
| Europe | $3.5 billion | $3.5 billion | 28.8% | 0.2% |
| Other Countries Outsideof the United States and Europe | $992 million | $881 million | 8.3% | 12.6% |

## What the Segment Figures Do Not Show

The rows above add up to 101% of Vertex Pharmaceuticals's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.

## Where These Numbers Come From

Every figure on this page is a value Vertex Pharmaceuticals reported in the segment note and revenue disclosures of its Form 10-K filed February 13, 2026 (accession 0000875320-26-000056), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.

Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.

## Frequently Asked Questions

### What are Vertex Pharmaceuticals's main products and services?

In its fiscal 2025 Form 10-K, Vertex Pharmaceuticals reports revenue for TRIKAFTAKAFTRIO, ALYFTREK, Manufactured Product Other, CASGEVY, JOURNAVX and Collaborative and Royalty.

### Which part of Vertex Pharmaceuticals brings in the most revenue?

TRIKAFTAKAFTRIO, with $10.3 billion of revenue in fiscal 2025, or 86% of the total.

### How much of Vertex Pharmaceuticals's revenue comes from outside the United States?

37% in fiscal 2025, by the geographic breakdown Vertex Pharmaceuticals reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.

## References

- [SEC EDGAR: VERTEX PHARMACEUTICALS INC / MA Form 10-K filed February 13, 2026](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)
- [SEC EDGAR: VERTEX PHARMACEUTICALS INC / MA annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=875320&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)
- [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets)

## Related Pages

- [Vertex Pharmaceuticals company dossier](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/)
- [Vertex Pharmaceuticals financial metrics](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/metrics/)
- [Vertex Pharmaceuticals financial risk indicators](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/risks/)
- [Vertex Pharmaceuticals peer comparison](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/competitors/)
- [Vertex Pharmaceuticals business model and revenue mix](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).